The hidden complexities of HIV’s Lenacapavir
Lenacapavir, an FDA-approved HIV injectable drug, has arrived in Uganda for preventive treatment, offering a convenient alternative to daily pills. The first shipment of 19,200 doses, supported by the Global Fund, requires one injection every six months to prevent the virus.
Lenacapavir is a highly effective HIV prevention drug, more than 99.9% effective in clinical trials. It can be used as a long-lasting treatment option for HIV-1. The drug is manufactured by Gilead Sciences and available as an injection and oral pills. Lenacapavir must be administered as part of a combination antiretroviral regimen to avoid rapid resistance development. The first shipment of 19,200 doses arrived in Uganda on February 24, 2026, supported by the Global Fund. The current supply is limited, with over 1.5 million people living with HIV in Uganda. Common side effects include injection site reactions, nausea, diarrhea, and headache.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.